Abstract
In press
Background. In recent years, the importance of the concept of cardiovascular-kidney-metabolic health has been increasingly emphasized, reflecting the close pathogenetic and clinical relationship between cardiovascular disease, renal dysfunction, and metabolic health in general. Cardiovascular and renal diseases, type 2 diabetes mellitus are key causes of high disability and mortality worldwide, and therefore impose a heavy economic burden on the health systems of all countries. The search for additional opportunities to provide more complete cardio- and nephroprotection in patients with diabetes mellitus and chronic kidney disease is a pressing issue at present.
Aim. Demonstration of the scientific and pathophysiological rationale for expanding the concept of metabolic syndrome to cardiovascular-renal-metabolic syndrome, as proposed by the American Heart Association (AHA).
Materials and Methods. This study is an analytical review of clinical and epidemiological studies from electronic databases, including PubMed and Google Scholar, mostly in the last five years, as well as official guidelines from the American Heart Association. Extensive population-based studies, including NHANES (National Health and Nutrition Examination Survey) III, were analyzed, and the pathophysiology, clinical manifestations, and treatment approaches for cardiovascular-renal-metabolic syndrome were examined. This study was conducted on the authors' own initiative and without additional funding.
Research Ethics. This work is a review of published scientific evidence and clinical guidelines and does not involve the implementation of interventions involving patients or the use of personal data, so local ethical committee approval was not required.
Results. In October 2023, the AHA for the first time officially defined what is called cardiovascular-kidney-metabolic syndrome, which is defined as a systemic disease characterized by pathophysiological interactions between metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multiple organ dysfunction and a high level of unfavorable cardiovascular outcomes.
Conclusions. This review describes approaches to the definition, principles of staging, strategies for prevention, as well as algorithms for the treatment of cardiovascular- kidney-metabolic syndrome, presents the key provisions for the management of cardiovascular-kidney-metabolic syndrome, proposed in the indicated clinical recommendations.
Keywords: therapy, cardiovascular diseases, chronic kidney disease, type 2 diabetes mellitus, obesity.
References
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association. Circulation. 2023;148(20):1606-1635. DOI: 10.1161/CIR.0000000000001184. PMID: 37807924.
Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). Journal of the American Society of Nephrology. 2002;13(5):1338-49. DOI: 10.1097/01.asn.0000013291.78621.26. PMID: 11961022.
An J, Sim JJ, Calhoun DA, Liu R, Wei R, Zhou H, et al. Apparent treatment- resistant hypertension: characteristics and prevalence in real-world environment of an integrated health system. J Hypertens. 2020;38(8):1603-1611. DOI: 10.1097/HJH.0000000000002419. PMID: 32251197.
An J, Tamura MK, Odden MC, Ni L, Thomas IC, Monthez-Rath ME, et al. Prevalence of apparent treatment-resistant hypertension in chronic kidney disease in two large US Health Care Systems. Clin J Am Soc Nephrol. 2022;17(10):1457-66. DOI: 10.2215/CJN.04110422. PMID: 36400564.
Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction. Circulation Research. 2021;128(7):951-68. DOI: 10.1161/CIRCRESAHA.121.318093. PMID: 33793327.
Khayyat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. J Am Coll Cardiol Heart Fail. 2021;9(2):100-11. DOI: 10.1016/j.jchf.2020.09.006. PMID: 33189627.
Ndumele ChE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A Synopsis of the Evidence for the Science and Clinical Management of CardiovascularKidneyMetabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023;148:163664. DOI: 10.1161/CIR.0000000000001186. PMID: 37807920.
PowellWiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e9841010. DOI: 10.1161/CIR.0000000000000973. PMID: 33882682.
Hill-Briggs F, Adler NE, Berkowitz SA, Chin MH, Gary-Webb TL, Navas-Acien A, et al. Social determinants of health and diabetes: a scientific review. Diabetes care. 2020;44(1):258-79. DOI: 10.2337/dci20-0053. PMID: 33139407.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):196686. DOI: 10.1097/HEP.0000000000000520. PMID: 37363821.
Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney international. 2022;102(2):24860. DOI: 10.1016/j.kint.2022.05.012. PMID: 35661785.
Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139:e84078. DOI: 10.1161/CIR.0000000000000664. PMID: 30852913.
Diaz-Santana MV, O’Brien KM. Park YMM, Sandler DP, Weinberg CR. Persistence of risk for type 2 diabetes after gestational diabetes mellitus. Diabetes Care. 2022;45(4):864-70. DOI: 10.2337/dc21-1430. PMID: 35104325.
Lloyd Jones DM, Allen NB, Anderson CA, Black T, Brewer LC, Foraker RE, et al. American Heart Association. Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146:e1843. DOI: 10.1161/CIR.0000000000001078. PMID: 35766027.
Beckman JA, Schneider PA, Conte MS. Advances in revascularization for peripheral artery disease: revascularization in PAD. Circulation research. 2021;128(12):1885912. DOI: 10.1161/CIRCRESAHA.121.318261. PMID: 34110904.
Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: oneyear results of the Look AHEAD Trial. Diabetes Care. 2007;30(6):137483. DOI: 10.2337/dc07-0048. PMID: 17363746.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52. DOI: 10.1016/S0140-6736(16)32064-5. PMID: 27887750.
Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of angiotensinconverting enzyme and angiotensin ii receptor blockers on allcause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and metaanalysis. Kidney and Blood Pressure Research. 2018;43(3):768-79. DOI: 10.1159/000489913. PMID: 29794446.
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International. 2021;99(3):S187. DOI: 10.1016/j.kint.2020.11.003. PMID: 33637192.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792. PMID: 30415628.
EMPA-Kidney Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2023;388(2):117-27. DOI: 10.1056/NEJMoa2204233. PMID: 36331190.
Agarwal R, Filippatos G, Pitt B, Anker S. D, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European heart journal. 2022;43(6):474-84. DOI: 10.1093/eurheartj/ehab777. PMID: 35023547.
Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive beneficial effects of betablockers to angiotensinconverting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. Journal of the American College of Cardiology. 1997;29(2):229-36 DOI: 10.1016/s0735-1097(96)00489-5. PMID: 9014971.
Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022;45(4):90918. DOI: 10.2337/dc21-1113. PMID: 35100355.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published corrections appear in Circulation. 2022;145:e1033; Circulation. 2022;146:e185; and Circulation. 2023;147:e674]. Circulation. 2022;145:e8951032. DOI: 10.1161/CIR.0000000000001063. PMID: 35363499.
Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HG, Ter Maaten JM, et al. Evidencebased medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145(9):693712. DOI: 10.1161/CIRCULATIONAHA.121.052792. PMID: 35226558.
Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodiumglucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a metaanalysis of individual participant data from randomized, controlled trials. Circulation. 2022;145(19):146070. DOI: 10.1161/CIRCULATIONAHA.121.057736. PMID: 35394821.
Donato AA. Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk. Annals of Internal Medicine. 2017;166(2):JC8. DOI: 10.7326/ACPJC-2017-166-2-008. PMID: 28114464.
Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020;141(16):e750-72. DOI: 10.1161/CIR.0000000000000748. PMID: 32148086.
Carballo D, Visseren FL, Mach F, Smulder Y. The "ten commandments" for the 2021 ESC Guidelines on CVD prevention. European Heart Journal. 2014;43(3):174-6. DOI: 10.1093/eurheartj/ehab742. PMID: 35080240.
Sugahara M, Pak WLW, Tanaka T, Tang SC, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology. 07 February 2021;26(6):491-500. DOI: 10.1111/nep.13860. PMID: 33550672.
Perl J, Brown EA, Chan CT, Couchoud C, Davies SJ, Kazancioğlu R, et al. Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) сontroversies сonference. Kidney international. 2023;103(5):842-58. DOI: 10.1016/j.kint.2023.01.006. PMID: 36731611.
Sarnak MJ, Auguste BL, Brown E, Chang AR, Chertow GM, Hannan M, et al. Cardiovascular effects of home dialysis therapies: a scientific statement from the American Heart Association. Circulation. 2022;146(11):e146-64. DOI: 10.1161/CIR.0000000000001088. PMID: 35968722.
Bansal N, Artinian NT, Bakris G, Chang T, Cohen J, Flythe J. American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular and Stroke Nursing; and Council on Epidemiology and Prevention. Hypertension in patients treated with in-center maintenance hemodialysis: current evidence and future opportunities: a scientific statement from the American Heart Association. Hypertension. 2023;80(6):e112-22. DOI: 10.1161/HYP.0000000000000230. PMID: 37092336.
De Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes care. 2022;45(12):3075-90. DOI: 10.2337/dci22-0027. PMID: 36189689.
Rangaswami J, McCullough PA. Heart failure in end-stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies. Seminars in nephrology. November 2018;38(6):600-17. DOI: 10.1016/j.semnephrol.2018.08.005. PMID: 30413254.
Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney international. 2014;85(1):49-61. DOI: 10.1038/ki.2013.444. PMID: 24284513.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

